• REASONS FOR THE SINGLE-USE LABEL
Why would the device manufacturers suddenly start labeling devices as "single-use only?" Several reasons come to mind.
Economics.
A precipitating event in this controversy was a relatively recent practice by manufacturers to relabel devices (such as surgical saw blades) from multiple use to single use only. 3 Hospitals continued to reprocess these devices just as they always had. Furthermore, if a device that has previously been used safely up to five times (especially an expensive one, such as a lumenless cardiac electrophysiology mapping catheter or a radiofrequency ablation catheter) 4 now can only be used once, the manufacturer can sell five times as many catheters and make five times as much money. Not a bad day's work for just adding a phrase to the label.
Product liability. If an injured party can successfully sue the deep-pocketed manufacturer of a product used in a medical procedure that caused an injury, that's scary, especially since the manufacturer has no control over what happens to the product once it is shipped to the hospital or physician who purchased it.
Safety. Some devices cannot be adequately cleaned without damaging them to the point of unreliability. For example, certain gastrointestinal biopsy forceps don't work as well after cleaning and sterilization, and some studies suggest that they really can't be adequately cleaned. 5 On the other hand, many devices can be safely reprocessed and reused.
B WHY SHOULD WE CARE?
The GAO acknowledged in their recent report that there is no evidence that reprocessing of single-use devices is a threat to public health. 3 One thing neither the GAO nor the FDA included in their respective reports is a recommendation for the development of criteria for application of the "single-use only" label. Why should providers or anyone else care? It is wasteful. Hospitals and physicians are currently operating under strong mandates to eliminate unnecessary costs from their procedures and practices. It is clearly wasteful to discard an expensive piece of equipment that can be safely and economically reused. 9 When the cost of using a serviceable, safe, reprocessed item is less than the cost of using a new one, why would we not want to do this? Cost-effectiveness is one of the linchpins of health care reform, and we must continue to increase it.
It will consume resources better directed toward quality improvement. Maintenance and improvement of quality are the hallmarks of modern health care. Current initiatives throughout the system to track and prevent errors are a part of this, and providers must keep the pressure on to assure that there are resources to beef up these efforts.
Such initiatives provide the data which prove the safety of current reprocessing methods, and we should not consume the valuable resources that fuel this process by arbitrarily driving up the expenses associated with clinical practice.
It will generate more medical waste. Recycling is one of the cornerstones of modern waste management. Medical waste is a particularly nasty byproduct of the health care system, for which nearly every practical method of disposal has come under serious criticism. A better solution is to reduce the generation of waste through recycling.
It is not necessary. As the GAO report on reprocessing confirmed, there is no evidence that reprocessing and reuse of single-use devices, as it is now practiced, has produced any significant problems. 3 Even new devices occasionally fail, and nothing suggests that reprocessed devices fail at a greater rate than new ones. 10 Infection from inadequately sterilized devices is a theoretical problem that has not been encountered in practice. So why institute a process that will definitely add cost but cannot improve quality?
• FDA RULING WAS A COMPROMISE
The involvement of the FDA came about in an attempt to find a compromise between banning the reuse of single-use devices vs doing nothing in response to the issues raised by the device manufacturers. On the face of it, this makes sense, because the focus of FDA oversight would be on patient safety rather than on economic benefits for the manufacturers. Reprocessing, whether by hospitals or third-party reprocessing companies, would be permitted, but it would only be allowed to occur under strict FDA supervision. There are several reasons why this compromise is not optimal.
These devices are not really remanufactured. To refer to the process of cleaning, testing, and resterilization by the term "remanufacturing," as the FDA does, 2 is more than a little pretentious, not to mention misleading. Throughout modern history, hospitals have been and remain in the business of resterilizing equipment used in the operating room and elsewhere, and this is not at issue. It is only understandable in the context of what the FDA wants to require of those who reprocess equipment marked, arbitrarily in many cases, "for single use only." The proposed requirements are essentially the same as those posed to the original manufacturers, including premarket testing, etc.
Furthermore, the FDA has classified the reprocessed equipment to be overseen into minimal (class I), intermediate (class II), and high (class III) risk. Included in the class II category are blood pressure cuffs. On the face of it, this seems ludicrous, and the whole business could use a dose of common sense.
No evidence there is a problem. If there is no problem (as confirmed by the GAO), 3 how will we know if the FDA process has been successful? If after a few years there have been no infections, for example, is someone going to claim that the FDA's oversight process is responsible for that?
New bureaucracy. The FDA is restricting its initial oversight to hospitals and thirdparty reprocessors. They acknowledge that many of the same activities they plan to regulate also take place in physicians' offices, but
The GAO found no evidence of a problem
DEVICE REPROCESSING CLOUGH AND COLLEAGUES
The whole business could use a dose of common sense they do not as yet have the manpower to deal with these settings. 1 You can bet they will correct that as quickly as they can.
Additional burdensome regulation. Hospitals and physicians' offices already carry a heavy regulatory burden. They get inspected by multiple federal and state agencies as well as by accrediting organizations, such as the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and the National Committee on Quality Assurance (NCQA). If there were a way to combine some of these inspections, that would at least be somewhat helpful.
Conflicting message. The government has a hard time getting agreement among its various departments and agencies as to what they really expect of health care providers, and many conflicting messages and initiatives, not all of which are clearly articulated, keep pouring forth. Are we supposed to be costeffective or to avoid any activity that might have the nefarious purpose of saving money? Are we supposed to protect the environment or load it up with perhaps five times the amount of waste we now generate?
• HOSPITALS, OFFICES WILL HAVE TO CHOOSE
It seems pretty clear that, at least for the present, hospitals that currently reprocess certain equipment will have some choices to make. If they wish to continue reprocessing, they will need to gear up to meet the new FDA requirements. The other choices are to stop doing the procedures altogether (unacceptable), use the equipment only once and discard it (expensive and wasteful), or to send out the used equipment to third-party reprocessors. While none of these options is particularly attractive, the last one may be the least of the evils for hospitals. The best option for individual physicians' offices, when it comes to that, is less clear. Cost and turnaround time (especially for expensive equipment) are the main problems with the last option, and hospitals will need to carefully consider the relative importance of these and other factors in making their decisions. In general, calcium channel blockers should be used with caution in patients with heart failure. NORVASC (5-10 mg per day) has been studied in a placebo-controlled trial of 1153 patients with NYHA Class III or IV heart failure on stable doses ol ACE inhibitor, digoxin, and diuretics. Follow-up was al least 6 months, with a mean of about 14 months. There was no overall adverse effecl on survival or cardiac morbidity (as defined by life-threatening arrhythmia, acute myocardial infarction, or hospitalization for worsened heart failure). NORVASC has been compared to placebo in four 8-12 week studies of patients with NYHA Class ll/lll heart failure, involving a total of 697 patients. In these studies, Ihere was no evidence of worsened heart failure based on measures ol exercise tolerance, NYHA classification, symptoms, or LVEF. Beta-Blocker Withdrawal: NORVASC is not a beta-blocker and therefore gives no protection against Ihe dangers of abrupt beta-blocker withdrawal; any such withdrawal should be by gradual reduction of the dose of beta-blocker.
Patients with Hepatic Failure: Since NORVASC is extensively metabolized by Ihe liver and the plasma elimination half-life (t '/¡) is 56 hours in patients with impaired hepatic function, caution should be exercised when administering NORVASC to patients with severe hepalic impairment. Drug Interactions: In vllro data in human plasma indicate that NORVASC has no effect on Ihe protein binding oi drugs tested (digoxin, phenytoin, warfarin, and indomethacin). Special studies have indicated that Ihe co-administration of NORVASC wilh digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers; lhat co-administration wilh cimetidine did not alter the pharmacokinetics of amlodipine; and that co-administration with warfarin did not change the warfarin prothrombin response time.
In clinical trials, NORVASC has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converfing enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. Drug/Laboratory Test Interactions: None known. Carcinogenesis, Mutagenesis, Impairment of Fertility: Rals and mice treated with amlodipine in Ihe diet for two years, at concentrations calculated to provide daily dosage levels of 0.5,1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (ior mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m? basis) was close to the maximum tolerated dose for mice but not for rats.
Mutagenicity studies revealed no drug related effects at either Ihe gene or chromosome levels. There was no effecl on the fertility of rats treated wilh amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* Ihe maximum recommended human dose of 10 mg on a mg/m 2 basis). Pregnancy Category C: No evidence of teratogenicity or other embryo/letal toxicity was found when pregnant rats or rabbils were treated orally with up to 10 mg/kg amlodipine (respectively 8 times* and 23 times" the maximum recommended human dose oi 10 mg on a mg/m? basis) during their respective periods of major organogenesis. However, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold) in rats administered 10 mg/kg amlodipine for 14 days before mating and throughout mating and gestation. Amlodipine has been shown to prolong both the gestation period and the duration of labor in rats at this dose. There are no adequate and well-controlled studies in pregnant women. Amlodipine should be used during pregnancy only if Ihe potential benefit justifies the potential risk to the felus. Nursing Mothers: It is not known whether amlodipine is excreted in human milk. In Ihe absence of this informalion, it is recommended lhat nursing be discontinued while NORVASC is administered. Pediatric Use: Safety and effectiveness ol NORVASC in children have not been established. ADVERSE REACTIONS: NORVASC has been evaluated for safely in more than 11,000 patients in U.S. and foreign clinical trials. In general, Ireatment with NORVASC was weil-lolerafed al doses up to 10 mg daily. Most adverse reactions reported during therapy with NORVASC were of mild or moderate severity In controlled clinical trials directly comparing NORVASC (N =1730) in doses up to 10 mg to placebo (N =1250). discontinuation ol NORVASC due to adverse reactions was required in only about 1.5% ol patients and was not significantly different from placebo (about 1%). The most common side effects are headache and edema. The incidence (%) of side effects which occurred in a dose related manner are as follows: edema (1.8% al 2.5 mg, 3.0% at 5.0 mg, and 10.8% at 10.0 mg, compared with 0.6% placebo); dizziness (1.1% at 2.5 mg, 3.4% at 5.0 mg, and 3.4% at 10.0 mg, compared with 1.5% placebo); flushing (0.7% al 2.5 mg. 1.4% al 5.0 mg, and 2.6% al 10.0 mg, compared with 0.0% placebo); and palpitation (0.7% at 2.5 mg, 1.4% at 5.0 mg, and 4.5% at 10.0 mg, compared with 0.6% placebo).
Other adverse experiences which were not clearly dose related but which were reported with an incidence greater than 1.0% in placebo-controlled clinical trials include the following: headache (7.3%, compared with 7.8% placebo); fatigue (4.5%, compared with 2.8% placebo); nausea (2.9%, compared with 1.9% placebo); abdominal pain (1.6%, compared with 0.3% placebo); and somnolence (1.4%, compared with 0.6% placebo).
For several adverse experiences that appear to be drug and dose related, there was a greater incidence in women than men associated with amlodipine treatment as follows: edema (5.6% in men, 14.6% in women, compared with a placebo incidence in men of 1.4% and 5.1% in women); flushing (1.5% in men, 4.5% in women, compared with a placebo incidence of 0.3% in men and 0.9% in women); palpitations (1.4% in men, 3,3% in women, compared with a placebo incidence of 0.9% in men and 0.9% in women); and somnolence (1.3% in men, 1.6% in women, compared with a placebo incidence of 0.8% in men and 0.3% in women).
The following events occurred in <1% but >0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship: cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, hypotension, peripheral ischemia, syncope, tachycardia, postural dizziness, postural hypotension, vasculitis; central and peripheral nervous system: hypoesthesia, neuropathy peripheral, paresthesia, tremor, vertigo; gastrointestinal: anorexia, constipation, dyspepsia,** dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia; general: allergic reaction, asthenia,** back pain, hot flushes, malaise, pain, rigors, weight gain; musculoskeletal system: arthralgia, arthrosis, muscle cramps,** myalgia; psychiatric: sexual dysfunction (male** and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization; respiratory system: dyspnea," epislaxis; skin and appendages: angioedema, erythema multiforme, pruritus,** rash,** rash erythematous, rash maculopapular; special senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus; urinary system: micturition frequency, micturition disorder, nocturia; autonomic nervous system: dry mouth, sweating increased; metabolic and nutritional: hyperglycemia, thirst; hemopoietic: leukopenia, purpura, thrombocytopenia.
The following events occurred in <0.1% of patients: cardiac failure, pulse irregularity, extrasysfoles, skin discoloration, urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia, hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, increased appetite, loose stools, coughing, rhinitis, dysuria, polyuria, parosmia, taste perversion, abnormal visual accommodation, and xerophthalmia.
Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as myocardial infarction and angina.
NORVASC therapy has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine.
The following postmarketing event has been reported infrequently where a causal relationship is uncertain: gynecomastia. In postmarketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis) in some cases severe enough to require hospitalization have been reported in association with use of amlodipine.
NORVASC has been used safely in patients with chronic obstructive pulmonary disease, well-compensated congestive heart failure, peripheral vascular disease, diabetes metlitus, and abnormal lipid profiles. OVERDOSAGE: Single oral doses of 40 mg/kg and 100 mg/kg in mice and rats, respectively, caused deaths. A single oral dose of 4 mg/kg or higher in dogs caused a marked peripheral vasodilation and hypotension.
Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a rellex tachycardia. In humans, experience wilh intentional overdosage of NORVASC is limited. Reports of intentional overdosage include a patient who ingested 250 mg and was asymptomatic and was not hospitalized; another (120 mg) was hospitalized, underwent gastric lavage and remained normotensive; the third (105 mg) was hospitalized and had hypotension (90/50 mmHg) which normalized following plasma expansion. A patient who took 70 mg amlodipine and an unknown quantity ol benzodiazepine in a suicide attempt developed shock which was refractory to treatment and died the following day with abnormally high benzodiazepine plasma concentration. A case of accidental drug overdose has been documented in a 19-month-old mate who ingested 30 mg amlodipine (about 2 mg/kg). During the emergency room presentation, vital signs were stable with no evidence of hypotension, but a heart rate of 180 bpm. Ipecac was administered 3.5 hours after ingestion and on subsequent observation (overnight) no sequelae were noted.
It massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. II hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As NORVASC is highly protein bound, hemodialysis is not likely to be of benefit. * Based on patient weight ol 50 kg. "These events occurred in less than 1% in placebo-controlled trials, but Ihe incidence ol these side effects was between 1% and 2% in all multiple dose studies.
More detailed professional information available on request.
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